Bristol-Myers Squibb was founded in 1887 and is headquartered in New York, US
Report incorrect company information
Key People/Management at Bristol-Myers Squibb
Giovanni Caforio
Chief Executive Officer
Charles Bancroft
Executive Vice President, CFO
Francis Cuss
Executive Vice President and Chief Scientific Officer
Lamberto Andreotti
Chairman, Board of Directors
Report incorrect company information
Bristol-Myers Squibb Office Locations
Bristol-Myers Squibb has offices in Zug, BI, Lawrence Township, Devens and in 176 other locations
New York, US (HQ)
345 Park Avenue
Report incorrect company information
Bristol-Myers Squibb Financials and Metrics
Bristol-Myers Squibb Financials
Bristol-Myers Squibb's revenue was reported to be $19.43 b in FY, 2016 which is a 17.3% increase from the previous period.
| USD | |
|---|---|
Revenue (Q3, 2017) | 5.3 b |
Gross profit (Q3, 2017) | 3.7 b |
Gross profit margin (Q3, 2017), % | 70.1% |
Net income (Q3, 2017) | 856 m |
Market capitalization (23-Apr-2018) | 83.7 b |
Cash (30-Sep-2017) | 4.6 b |
EV | 86.1 b |
Bristol-Myers Squibb's current market capitalization is $83.7 b.
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 16.4 b | 15.9 b | 16.6 b | 19.4 b |
Revenue growth, % | (3%) | 4% | 17% | |
Cost of goods sold | 4.6 b | 3.9 b | 3.9 b | 4.9 b |
Gross profit | 11.8 b | 11.9 b | 12.7 b | 14.5 b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.1 b | 3.8 b | 3.9 b | 3.9 b | 4 b | 4.2 b | 4.1 b | 4.4 b | 4.9 b | 4.9 b | 4.9 b | 5.1 b | 5.3 b |
Cost of goods sold | 1.2 b | 968 m | 991 m | 1 b | 847 m | 1 b | 1.1 b | 1.1 b | 1.2 b | 1.3 b | 1.3 b | 1.6 b | 1.6 b |
Gross profit | 2.9 b | 2.8 b | 2.9 b | 2.9 b | 3.2 b | 3.2 b | 3 b | 3.3 b | 3.7 b | 3.6 b | 3.7 b | 3.6 b | 3.7 b |
Gross profit Margin, % | 71% | 75% | 75% | 74% | 79% | 76% | 73% | 76% | 75% | 73% | 74% | 70% | 70% |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 3.6 b | 5.6 b | 2.4 b | 4.2 b |
Inventories | 1.5 b | 1.6 b | 1.2 b | 1.2 b |
Current Assets | 18.9 b | 14.6 b | 10.4 b | 13.7 b |
Goodwill | 7.1 b | 7 b | 6.9 b | 6.9 b |
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|
Cash | 4.2 b | 4 b | 2.6 b | 2.9 b | 3.4 b | 3.9 b | 3.5 b | 4.6 b |
Inventories | 1.3 b | 1.1 b | 1.3 b | 1.4 b | 1.5 b | 1.4 b | 1.2 b | 1.3 b |
Current Assets | 13.1 b | 12.9 b | 11.2 b | 12.3 b | 13.2 b | 13.6 b | 14.3 b | 15 b |
Goodwill | 7 b | 7 b | 6.9 b | 6.9 b | 6.9 b | 6.9 b | 6.9 b | 6.9 b |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 2.6 b | 2 b | 1.6 b | 4.5 b |
Inventories | (45 m) | (254 m) | 97 m | (152 m) |
Accounts Payable | 412 m | (44 m) | (919 m) | 104 m |
Cash From Operating Activities | 3.5 b | 3.1 b | 1.8 b | 2.9 b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.8 b | 936 m | 1.3 b | 2 b | 1.2 b | 1.1 b | 1.8 b | 1.2 b | 2.4 b | 3.6 b | 1.5 b | 2.4 b | 3.3 b |
Inventories | (8 m) | (144 m) | (157 m) | (162 m) | 51 m | 162 m | 231 m | (44 m) | (111 m) | (107 m) | (71 m) | (58 m) | 7 m |
Accounts Payable | 301 m | (12 m) | (112 m) | 63 m | (83 m) | (618 m) | (1.2 b) | (77 m) | (36 m) | (142 m) | (114 m) | (85 m) | 63 m |
Cash From Operating Activities | 2.1 b | 1.7 b | 2.6 b | 626 m | 697 m | 1.2 b | 25 m | 1.4 b | 2.4 b | 4.2 b |
| USD | Y, 2017 |
|---|---|
EV/CFO | 20.7 x |
EV/FCF | 25.6 x |
Revenue/Employee | 210.2 k |
Financial Leverage | 2.3 x |
Bristol-Myers Squibb Operating Metrics
| Y, 2015 | Y, 2016 | |
|---|---|---|
Phase III Trials Products | 2 | 8 |
Projects in R&D Pipeline | 32 | 44 |
Report incorrect company information
